{"product_id":"mri-for-prostate-cancer-screening-the-reimagine-study-explained","title":"MRI for Prostate Cancer Screening: The ReIMAGINE Study Explained","description":"\u003cp\u003eThe ReIMAGINE study, published in BMJ Oncology, investigated whether MRI scans could serve as a primary screening tool for prostate cancer, working independently of—or alongside—the traditional PSA blood test. In a group of 303 men aged 50–75 who responded to a general practice (GP) invitation for a prostate health check, 1 in 6 men (16%) had a lesion visible on MRI, and 9.6% were ultimately diagnosed with clinically significant prostate cancer. Strikingly, more than half of the men with clinically significant cancer had PSA levels below the commonly used threshold of 3 ng\/mL, meaning the PSA test alone would have missed them. These results suggest that an MRI-led approach to screening could detect more clinically significant cancers while potentially reducing the overdiagnosis and overtreatment associated with PSA-based screening.\u003c\/p\u003e\n\n\u003ch1\u003eMRI for Prostate Cancer Screening: The ReIMAGINE Study Explained\u003c\/h1\u003e\n\n\u003ch2\u003eTable of Contents\u003c\/h2\u003e\n\u003cul\u003e\n\u003cli\u003e\u003ca href=\"#ddn-key-points\"\u003eKey Points\u003c\/a\u003e\u003c\/li\u003e\n\n  \u003cli\u003e\u003ca href=\"#why-it-matters\"\u003eWhy This Research Matters\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#what-we-knew\"\u003eWhat We Already Knew: PSA Testing Has Limits\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#study-design\"\u003eHow the Study Was Designed\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#participants\"\u003eWho Took Part in the Study\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#screening-procedures\"\u003eThe Screening Procedures: MRI and PSA\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#response-rates\"\u003eKey Finding: Who Responded to the Invitation?\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#mri-results\"\u003eKey Finding: What Did the MRI Scans Show?\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#psa-density-results\"\u003eKey Finding: PSA Density Results\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#cancer-detection\"\u003eKey Finding: Cancer Detection After NHS Assessment\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#clinical-implications\"\u003eClinical Implications: What This Means for Patients\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#limitations\"\u003eStudy Limitations: What It Couldn't Prove\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#future-research\"\u003eFuture Research and Recommendations\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#ddn-faq\"\u003eFrequently Asked Questions\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"#source\"\u003eSource Information\u003c\/a\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003c!-- ddn:keypoints:start --\u003e\n\u003ch2 id=\"ddn-key-points\"\u003eKey Points\u003c\/h2\u003e\n\u003cul\u003e\n\u003cli\u003eIn a study of 303 men aged 50–75, 1 in 6 had a lesion visible on MRI, and 9.6% were diagnosed with clinically significant prostate cancer.\u003c\/li\u003e\n\u003cli\u003eMore than half of men with clinically significant cancer had PSA below 3 ng\/mL, so PSA testing alone would have missed them.\u003c\/li\u003e\n\u003cli\u003eOnly 1% of screened men were diagnosed with clinically insignificant cancer, compared with about half in PSA-based screening trials.\u003c\/li\u003e\n\u003cli\u003eResponse to the invitation was lower among black and Asian men, despite black men having a higher risk of prostate cancer.\u003c\/li\u003e\n\u003cli\u003eThe study was a single-centre feasibility study with no long-term follow-up, so it cannot prove that MRI screening reduces deaths.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c!-- ddn:keypoints:end --\u003e\n\n\n\u003ch2 id=\"why-it-matters\"\u003eWhy This Research Matters\u003c\/h2\u003e\n\n\u003cp\u003eProstate cancer is the most common cancer in men in the UK, and the second most common cause of cancer-related death. The UK currently has no formal national screening programme for prostate cancer, yet the country's age-standardised prostate cancer-specific mortality rate is 12.4 per 100,000 population. That is notably higher than other developed nations: the USA has a rate of 8.2 per 100,000, France 8.4, Spain 7.3, and Italy 5.9 per 100,000.\u003c\/p\u003e\n\n\u003cp\u003eThe absence of a screening programme means many cancers are found late. However, past attempts at screening have been controversial, because they can cause more harm than good in some men. This study — called ReIMAGINE — was designed to test a new approach: using MRI scans as a primary screening tool, rather than relying on the PSA blood test first.\u003c\/p\u003e\n\n\u003ch2 id=\"what-we-knew\"\u003eWhat We Already Knew: PSA Testing Has Limits\u003c\/h2\u003e\n\n\u003cp\u003eThe European Randomised Screening for Prostate Cancer (ERSPC) study demonstrated that organised screening can reduce prostate cancer death rates. Men screened using a PSA threshold of \u0026gt;3 ng\/mL, or an abnormal digital rectal examination (DRE), followed by a standard transrectal biopsy, had a 20% reduction in prostate cancer-specific mortality at 16 years of follow-up compared with unscreened men. But this benefit came at a significant price: overdiagnosis.\u003c\/p\u003e\n\n\u003cp\u003eWhen PSA is used as a triage test and transrectal biopsy as the verification step, roughly half of all detected cancers are low grade — meaning they are unlikely to ever cause symptoms or threaten a man's life. Even so, many men with these low-risk cancers accept radical treatment, exposing them to unnecessary side effects such as urinary incontinence and erectile dysfunction.\u003c\/p\u003e\n\n\u003cp\u003eA large UK Cluster Randomised Trial involving more than 400,000 men, which used a single PSA test, found similar prostate cancer-specific and overall mortality rates between screened men and controls when analysed at 10 years. It did, however, find an increased proportion of men diagnosed with low-risk prostate cancer in the screened group. This problem of overdiagnosis and the associated personal and economic costs of continued monitoring — or \"overtreatment\" — has been a significant barrier to introducing PSA-based screening programmes.\u003c\/p\u003e\n\n\u003cp\u003eThe PROMIS study, conducted in a clinical population of men with raised PSA or abnormal DRE, found that standard transrectal biopsy missed over half of the significant cancers that were visible on MRI. It also showed that MRI lesions scoring 4 out of 5 had a greater than 50% likelihood of harbouring clinically significant cancer, and lesions scoring 5 out of 5 had a greater than 70% likelihood. MRI lesions are positively correlated with higher histological grade and prostate cancer volume.\u003c\/p\u003e\n\n\u003cp\u003eGiven that PSA and traditional transrectal biopsy both have significant limitations, the researchers behind ReIMAGINE asked a fundamental question: \u003cstrong\u003eHow would MRI perform on its own if used in an age-defined — not PSA-defined — population?\u003c\/strong\u003e\u003c\/p\u003e\n\n\u003ch2 id=\"study-design\"\u003eHow the Study Was Designed\u003c\/h2\u003e\n\n\u003cp\u003eThe ReIMAGINE study was a prospective, single-centre feasibility study, designed to assess whether a screening approach using both PSA and MRI could work in a community setting. University College London (UCL) was the study sponsor (reference 122665). The study was funded by the Medical Research Council (MRC) (grant number MR\/R014043\/1) and Cancer Research UK (CRUK), and it was registered at ClinicalTrials.gov under the identifier NCT04063566.\u003c\/p\u003e\n\n\u003cp\u003eA key feature of the funding process was patient and public involvement (PPI). Patients were involved in the planning and design of the research from the outset. They were interviewed by the grant awarding committee alongside two senior researchers, co-developed the screening protocol, and suggested lowering the age of invitation from a proposed higher threshold down to 50, because of concerns about missed significant cancers in younger men. When the study was paused for COVID-19 in April 2020, the PPI group were instrumental in designing modifications to allow recruitment to continue safely, which ultimately led to recruitment finishing ahead of the original planned schedule.\u003c\/p\u003e\n\n\u003ch2 id=\"participants\"\u003eWho Took Part in the Study\u003c\/h2\u003e\n\n\u003cp\u003ePotential participants were identified by searching existing patient databases at eight London GP surgeries. Men aged 50 to 75, who had no prior diagnosis of prostate cancer, were identified and randomly selected for invitation.\u003c\/p\u003e\n\n\u003cp\u003eA single letter explaining the study was sent to each man, inviting him to contact the study team to check eligibility. Eligible men who wanted to take part were offered a screening visit at University College London Hospital Trust.\u003c\/p\u003e\n\n\u003cp\u003eIn total, 2,096 men were invited across the eight GP practices. Of those, \u003cstrong\u003e457 men (22%) contacted the study team in response to the invitation\u003c\/strong\u003e. Ultimately, 309 men attended for screening. The number of men screened was limited by the availability of a fixed number of MRI slots, so not all eligible responders were able to participate.\u003c\/p\u003e\n\n\u003ch2 id=\"screening-procedures\"\u003eThe Screening Procedures: MRI and PSA\u003c\/h2\u003e\n\n\u003cp\u003eThe screening visit included the formal consent process. Each man who consented had a PSA blood test and a screening MRI (sMRI). The PSA density — a measure that relates the PSA level to the volume of the prostate gland — was calculated using the prostate volume measured on the MRI.\u003c\/p\u003e\n\n\u003cp\u003eThe MRI protocol was designed to be efficient and feasible for a screening setting. It was carried out on a 3 Tesla scanner, with a total scan time of under 20 minutes. The clinical sequences included T2-weighted axial turbo spin echo and diffusion-weighted imaging using a high b value of 2000 s\/mm², with an acquisition time of under 10 minutes. Importantly, contrast enhancement was not used, and there were no apparent diffusion coefficient (ADC) sequences — simplifying the scan and making it quicker than a standard diagnostic MRI.\u003c\/p\u003e\n\n\u003cp\u003eEach MRI was scored as positive or negative independently by two radiologists, according to pre-defined criteria. If the two radiologists did not agree on the screening result, a third reviewer was brought in to settle the case.\u003c\/p\u003e\n\n\u003cp\u003eMen were deemed \"screen positive\" if they had either a positive sMRI or a PSA density above 0.12 ng\/mL². This threshold is a recognised clinical marker of increased risk. Screen-negative men were informed of their result and exited the study. Screen-positive men were advised to have a referral for National Health Service (NHS) assessment through an urgent suspected cancer pathway.\u003c\/p\u003e\n\n\u003cp\u003eBiopsies were performed if indicated after multiparametric MRI within a standard NHS pathway, at one of two London hospitals. A transperineal approach was used, with targeted biopsy of the MRI lesion and systematic sampling of the peripheral zones of the prostate. \u003cstrong\u003eClinically significant cancer was defined as any Gleason pattern 4 or above\u003c\/strong\u003e — a standard definition used to distinguish aggressive cancers from indolent ones.\u003c\/p\u003e\n\n\u003ch2 id=\"response-rates\"\u003eKey Finding: Who Responded to the Invitation?\u003c\/h2\u003e\n\n\u003cp\u003eResponse to the invitation was strongly influenced by age and ethnicity. Multivariable logistic regression analysis showed that older white men were the most likely to respond. Men in the 65–70 age band had the highest acceptance rate, taking note that prostate cancer incidence rises with age.\u003c\/p\u003e\n\n\u003cul\u003e\n  \u003cli\u003eMen aged 50–55: 19% accepted the invitation\u003c\/li\u003e\n  \u003cli\u003eMen aged 55–60: 19% accepted\u003c\/li\u003e\n  \u003cli\u003eMen aged 60–65: 25% accepted\u003c\/li\u003e\n  \u003cli\u003eMen aged 65–70: 32% accepted\u003c\/li\u003e\n  \u003cli\u003eMen aged over 70: 28% accepted\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eThe most striking disparity was by ethnicity. Black men had only \u003cstrong\u003eone-fifth of the response rate of white men\u003c\/strong\u003e (odds ratio 0.21 in the univariable model, p\u0026lt;0.001; odds ratio 0.22 in the multivariable model, p\u0026lt;0.001). Asian men also had significantly lower response rates compared with white men (odds ratio 0.32, p\u0026lt;0.001). This matters clinically because black men in the UK are known to have a higher risk of developing and dying from prostate cancer.\u003c\/p\u003e\n\n\u003cp\u003eDeprivation, measured using the Index of Multiple Deprivation (IMD), did not differ between responders and non-responders. The ethnicity distribution of the invited men reflected the ethnicity distribution across London as a whole, meaning the lower response rate among black and Asian men was not simply because fewer men from these groups were invited.\u003c\/p\u003e\n\n\u003cp\u003eIt is worth noting that not all men who responded could actually be scanned. MRI slots were limited by fixed funding, and men were allocated on a \"first come, first served\" basis.\u003c\/p\u003e\n\n\u003ch2 id=\"mri-results\"\u003eKey Finding: What Did the MRI Scans Show?\u003c\/h2\u003e\n\n\u003cp\u003eOf the 303 men who completed both screening tests (the MRI and the PSA test), the mean age was 61.9 years (range 50–77, standard deviation 7.23 years). The median PSA was 1.2 ng\/mL (interquartile range 0.7–2.2), and the median prostate volume was 29 mL. The median PSA density was 0.04 ng\/mL² (interquartile range 0.03–0.06).\u003c\/p\u003e\n\n\u003cp\u003eThe central finding of the study: \u003cstrong\u003eOne in six men (48 of 303, 16%) had a positive screening MRI\u003c\/strong\u003e — meaning a lesion was visible that warranted further investigation.\u003c\/p\u003e\n\n\u003cp\u003eEven more notable was the relationship between MRI findings and PSA levels. Of the 48 men with a positive MRI, \u003cstrong\u003e32 men (67%) had a PSA below 3 ng\/mL\u003c\/strong\u003e — a level that would typically be considered \"normal\" and would not trigger further investigation under traditional PSA-based screening protocols. These men would have been falsely reassured if they had been screened with PSA alone.\u003c\/p\u003e\n\n\u003cp\u003eIt is also worth noting that none of the 13 black men in the study had a positive MRI, although the small numbers mean this result should be interpreted cautiously. Logistic regression adjusting for age, ethnicity, and deprivation showed that older age and Asian or other ethnicity were associated with a higher likelihood of a positive MRI.\u003c\/p\u003e\n\n\u003ch2 id=\"psa-density-results\"\u003eKey Finding: PSA Density Results\u003c\/h2\u003e\n\n\u003cp\u003ePSA density is calculated by dividing the PSA level by the prostate volume. A higher PSA density suggests that the PSA is coming from cancer tissue rather than from benign prostate enlargement. In this study, a PSA density of \u0026gt;0.12 ng\/mL² was considered a positive screening result, even if the MRI was negative.\u003c\/p\u003e\n\n\u003cp\u003eOf the 255 men with a negative MRI, \u003cstrong\u003e16 men (5%) had a raised PSA density\u003c\/strong\u003e of \u0026gt;0.12 ng\/mL² and were therefore also recommended for an NHS referral for further assessment. Three of these 16 men (19%) had a PSA below 3 ng\/mL, again illustrating that relying on an absolute PSA threshold can miss some men at risk.\u003c\/p\u003e\n\n\u003cp\u003ePSA density was significantly higher in black and Asian men, and in men aged 65–70, compared with other groups. These differences reflect known variations in PSA levels and prostate size across different populations.\u003c\/p\u003e\n\n\u003ch2 id=\"cancer-detection\"\u003eKey Finding: Cancer Detection After NHS Assessment\u003c\/h2\u003e\n\n\u003cp\u003eA total of 64 of the 303 screened men (21%) had either a positive screening MRI or a raised PSA density. These men were recommended for further assessment through the NHS cancer pathway, which was carried out according to local GP practice preference and outside of the study protocol.\u003c\/p\u003e\n\n\u003cp\u003eThe results of that assessment were sobering and encouraging at the same time.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eAmong the 48 men with a positive screening MRI:\u003c\/strong\u003e\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003e25 men (52%) were found to have clinically significant prostate cancer after biopsy\u003c\/li\u003e\n  \u003cli\u003e2 men (4%) had clinically insignificant cancer\u003c\/li\u003e\n  \u003cli\u003e21 men (44%) had no cancer detected on biopsy\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eAmong the 16 men who had a negative MRI but a raised PSA density:\u003c\/strong\u003e\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003e4 men (25%) were found to have clinically significant cancer\u003c\/li\u003e\n  \u003cli\u003e1 man (6%) had clinically insignificant cancer\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eIn total, \u003cstrong\u003e29 of the 303 screened men (9.6%) were diagnosed with clinically significant prostate cancer\u003c\/strong\u003e, and 3 men (1%) were diagnosed with clinically insignificant cancer. This means that fewer than 1% of all screened men were \"overdiagnosed\" with low-risk disease — a striking contrast to the overdiagnosis rates seen with traditional PSA-based screening, where half of detected cancers are low grade.\u003c\/p\u003e\n\n\u003cp\u003ePerhaps the most clinically important finding relates to PSA thresholds. Of the 25 men with a positive MRI and clinically significant cancer, \u003cstrong\u003e15 men (60%) had a PSA below 3 ng\/mL\u003c\/strong\u003e. More than half of the men with significant disease would have been missed by a PSA-based screening strategy that uses the conventional threshold of \u0026gt;3 ng\/mL for biopsy referral.\u003c\/p\u003e\n\n\u003cp\u003eIn a detailed analysis of the 17 men with a positive MRI and a PSA below 3 ng\/mL, the biopsy results included:\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003e2 Gleason 3+3 cancers (low-risk)\u003c\/li\u003e\n  \u003cli\u003e13 Gleason 3+4 cancers with a mean cancer core length (MCCL) of 7 mm\u003c\/li\u003e\n  \u003cli\u003e1 Gleason 4+3 cancer with a 3 mm MCCL\u003c\/li\u003e\n  \u003cli\u003e1 Gleason 4+5 cancer with a 9 mm MCCL\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eThe Gleason 4+5 cancer is particularly notable, as a Gleason pattern 5 represents a highly aggressive form of the disease that carries a substantial risk of progression and death if left untreated.\u003c\/p\u003e\n\n\u003ch2 id=\"clinical-implications\"\u003eClinical Implications: What This Means for Patients\u003c\/h2\u003e\n\n\u003cp\u003eThese findings have significant implications for how prostate cancer screening might be conducted in the future. MRI as a triage test — used between a raised PSA or abnormal DRE and a biopsy — has been recommended in UK guidelines since 2018. It is now also recommended in the European Association of Urology guidelines and by the American Urology Association. But this study goes a step further, exploring whether MRI could be the primary screening test itself.\u003c\/p\u003e\n\n\u003cp\u003eThe key takeaways for patients are clear:\u003c\/p\u003e\n\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eThe PSA test is not enough on its own.\u003c\/strong\u003e More than half of the men in this study with clinically significant cancer — and two-thirds of men with a positive MRI — had PSA below 3 ng\/mL. If PSA had been used alone as a triage test, these cancers would not have been detected.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eMRI can detect significant cancers early.\u003c\/strong\u003e One in six men had a lesion visible on MRI, and of those who went on to have a biopsy, more than half had clinically significant cancer.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eOverdiagnosis may be dramatically reduced.\u003c\/strong\u003e Only 1% of screened men were diagnosed with clinically insignificant cancer, compared with roughly half of all cancers detected in PSA-based screening trials being low grade.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eAn MRI result must be combined with clinical judgement.\u003c\/strong\u003e The 4% of men with a negative MRI but raised PSA density still had a 25% chance of harbouring clinically significant cancer, so MRI alone was not perfect in this study.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eThe researchers note that a widely used approach at the time of the study was to offer further assessment when PSA was \u0026gt;3 ng\/mL. Given their findings, they reference the work of Eklund and colleagues, who used a PSA cut-off of 1.6 ng\/mL for further assessment. The ReIMAGINE team suggests that the use of PSA and MRI as independent risk assessment tools deserves further exploration in a larger screening study.\u003c\/p\u003e\n\n\u003ch2 id=\"limitations\"\u003eStudy Limitations: What It Couldn't Prove\u003c\/h2\u003e\n\n\u003cp\u003eIt is important to understand this study's limitations before drawing broad conclusions. This was a feasibility study, carried out in a relatively small sample of men from a number of London GP practices that had been nominated as research-active. Because the scanning centre was based in London, it was not practical to send invitations more widely.\u003c\/p\u003e\n\n\u003cp\u003eThe response rate of 22% is also a concern. A single paper invitation was sent, without the general advertising and awareness campaigns that formal UK screening programmes typically include. Moreover, the study was severely affected by the COVID-19 pandemic, which paused recruitment from April to August 2020. At that time, many people were avoiding healthcare settings entirely, and it is likely that the pandemic materially reduced the response rate.\u003c\/p\u003e\n\n\u003cp\u003eSeveral other limitations deserve attention:\u003c\/p\u003e\n\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eSelection bias:\u003c\/strong\u003e Men who respond to a screening invitation may be healthier, more health-conscious, or have different risk profiles than non-responders. Notably, older white men were more likely to respond, and black men — who have a higher risk of prostate cancer — had only one-fifth the response rate of white men.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eActual screening numbers were limited:\u003c\/strong\u003e Not all men who responded could be scanned because funding limited the number of available MRI slots. This could introduce additional bias.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eSingle-centre design:\u003c\/strong\u003e The MRI scans were performed and read at a single London university hospital, and the study setting was hospital-based. A true screening programme would need to be delivered across multiple centres, in specialised screening facilities, with machines of consistent high quality.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eNo long-term follow-up:\u003c\/strong\u003e The study assessed only the outcome of the immediate NHS assessment. It did not determine whether detecting these cancers actually reduces prostate cancer mortality over time — the ultimate measure of any screening programme's value.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eBiopsy decisions were outside the study protocol:\u003c\/strong\u003e Men who screened positive were assessed and biopsied through the standard NHS pathway, according to local GP practice preference. This introduces variability in how and whether biopsies were performed.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eIt is also important to note that the study ended when screening test results were provided. Further assessment, including biopsy, was done via the usual NHS pathway — following the same pattern as UK screening programmes for breast, colorectal, and cervical cancer, but differing from some other prostate cancer screening studies that included biopsy within the study protocol.\u003c\/p\u003e\n\n\u003ch2 id=\"future-research\"\u003eFuture Research and Recommendations\u003c\/h2\u003e\n\n\u003cp\u003eDespite these limitations, the ReIMAGINE study provides crucial normative data on the prevalence of MRI lesions in an age-defined, systematically recruited community population — data that have not been previously reported. This information will allow researchers to model the performance of an MRI-based screening strategy and design the next stage of research into MRI's role as a primary screening test.\u003c\/p\u003e\n\n\u003cp\u003eThe researchers make several recommendations for future work:\u003c\/p\u003e\n\n\u003col\u003e\n  \u003cli\u003e\n\u003cstrong\u003eEvaluate MRI-led screening in a larger UK population.\u003c\/strong\u003e The next step is to assess whether an MRI-led approach can maintain the 20% reduction in prostate cancer mortality seen with formal PSA-based screening, while reducing overdiagnosis and overtreatment.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eExplore community-based MRI delivery.\u003c\/strong\u003e A screening programme would need to be delivered at specialised screening centres with consistent high-quality image acquisition and reporting. The use of mobile MRI scanners — similar to those used in some breast screening programmes — should be assessed.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eAddress differential response rates.\u003c\/strong\u003e The fact that older white men were most likely to respond, while black men were least likely to respond despite having the highest risk of prostate cancer, needs to be actively addressed. In an ideal screening programme, the likelihood of response should be proportionate to the risk of disease in that group. A recent model-based analysis of USA SEER data suggested that increasing the intensity of PSA screening in black men between the ages of 45 and 65 could help reduce disparities.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eConsider repeat screening intervals.\u003c\/strong\u003e The high prevalence of lesions on first screen might be balanced by lower detection on re-screening. Repeated screening of the same men after an appropriate interval would help answer this question.\u003c\/li\u003e\n\u003c\/ol\u003e\n\n\u003cp\u003eThe response rate of 22% was achieved during a global pandemic when people were actively discouraged from attending healthcare settings. A single paper invitation, without repeated reminders or public health campaigns, achieved a level of uptake that the researchers believe is likely to increase in non-pandemic times.\u003c\/p\u003e\n\n\u003cp\u003eFor individual men, the message from this study is that PSA testing alone has significant blind spots. A man with a PSA below 3 ng\/mL can still harbour an aggressive prostate cancer — and in this study, more than half of men with clinically significant disease fell into that category. While the ReIMAGINE findings do not yet support widespread MRI screening outside of research settings, they strengthen the case for discussing prostate cancer risk with a doctor, particularly for men in higher-risk groups such as black men and those with a family history of prostate cancer.\u003c\/p\u003e\n\n\u003cp\u003eThe study's conclusion is clear: prostate MRI may have value in screening independently of PSA, and these data will inform larger prostate cancer screening studies designed to find the optimal balance between catching significant cancers early and avoiding the harms of overdiagnosis.\u003c\/p\u003e\n\n\u003c!-- ddn:faq:start --\u003e\n\u003ch2 id=\"ddn-faq\"\u003eFrequently Asked Questions\u003c\/h2\u003e\n\u003ch3\u003eWhat was the ReIMAGINE study?\u003c\/h3\u003e\n\u003cp\u003eIt was a prospective, single-centre feasibility study that tested whether MRI scans could be used as a primary screening tool for prostate cancer, either alone or alongside the PSA blood test. It involved 303 men aged 50–75 who responded to a GP invitation for a prostate health check. The study was funded by the Medical Research Council and Cancer Research UK.\u003c\/p\u003e\n\u003ch3\u003eWho was eligible to take part in the ReIMAGINE study?\u003c\/h3\u003e\n\u003cp\u003eMen aged 50 to 75 who had no prior diagnosis of prostate cancer were identified from eight London GP surgeries and randomly selected for invitation. A single letter invited them to contact the study team to check eligibility. In total, 2,096 men were invited, 457 responded, and 309 attended for screening.\u003c\/p\u003e\n\u003ch3\u003eWhat did the screening involve?\u003c\/h3\u003e\n\u003cp\u003eEach man who consented had a PSA blood test and a screening MRI. The MRI was done on a 3 Tesla scanner, took under 20 minutes, and did not use contrast dye. PSA density was calculated using prostate volume measured on the MRI. Men were considered screen positive if the MRI was positive or PSA density was above 0.12 ng\/mL².\u003c\/p\u003e\n\u003ch3\u003eDoes the ReIMAGINE study prove MRI screening saves lives?\u003c\/h3\u003e\n\u003cp\u003eNo. The study assessed only the immediate NHS assessment after screening. It did not determine whether detecting these cancers reduces prostate cancer mortality over time. The researchers say the findings do not yet support widespread MRI screening outside of research settings, and larger studies are needed.\u003c\/p\u003e\n\u003ch3\u003eIf my PSA is below 3 ng\/mL but I'm still worried about prostate cancer, when should I get a second opinion?\u003c\/h3\u003e\n\u003cp\u003eA PSA below 3 ng\/mL does not rule out significant disease. Among men with a positive screening MRI and clinically significant prostate cancer, 60% had a PSA under 3 ng\/mL, and two-thirds of men with a positive MRI had PSA below that level. A second opinion is worth seeking when PSA alone has been used to reassure you, when MRI findings and PSA density give conflicting results, or when a raised PSA density above 0.12 ng\/mL² has not led to further assessment. Diagnostic Detectives Network provides independent expert second opinions.\u003c\/p\u003e\n\u003c!-- ddn:faq:end --\u003e\n\n\u003ch2 id=\"source\"\u003eSource Information\u003c\/h2\u003e\n\n\u003cp\u003e\u003cstrong\u003eOriginal article title:\u003c\/strong\u003e Prevalence of MRI lesions in men Reimagine study Emberton\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eAuthors:\u003c\/strong\u003e Caroline M Moore, Elena Frangou, Neil McCartan, Aida Santaolalla, Douglas Kopcke, Giorgio Brembilla, Joanna Hadley, Francesco Giganti, Teresa Marsden, Mieke Van Hemelrijck, Fiona Gong, Alex Freeman, Aiman Haider, Steve Tuck, Nora Pashayan, Thomas Callender, Saran Green, Louise C Brown, Shonit Punwani, Mark Emberton, on behalf of the ReIMAGINE Study group.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eJournal:\u003c\/strong\u003e BMJ Oncology, 2023; Volume 2, article e000057. Published online 21 August 2023. doi:10.1136\/bmjonc-2023-000057\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eTrial registration:\u003c\/strong\u003e ClinicalTrials.gov identifier NCT04063566\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eFunding:\u003c\/strong\u003e Medical Research Council (grant number MR\/R014043\/1) and Cancer Research UK.\u003c\/p\u003e\n\n\u003cp\u003e\u003cem\u003eThis patient-friendly article is based on peer-reviewed research. It is intended for informational purposes only and does not constitute medical advice. Men with questions about prostate cancer screening should consult their healthcare provider.\u003c\/em\u003e\u003c\/p\u003e","brand":"DiagnosticDetectives.Com","offers":[{"title":"Default Title","offer_id":47699391545500,"sku":null,"price":0.0,"currency_code":"USD","in_stock":true}],"url":"https:\/\/diagnosticdetectives.com\/fr\/products\/mri-for-prostate-cancer-screening-the-reimagine-study-explained","provider":"DiagnosticDetectives.Com","version":"1.0","type":"link"}